Thomas Gabrielczyk's articles

  1. Biotechnology
The therapeutic landscape for relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) is evolving toward targeted T-cell based immunotherapies, including CD19-targeted CAR-T and CD3xCD20 T-cell engaging (TCE) bispecificantibodies. Yet, there remains an unmet medical need for patients who are refractory to, or ineligible for these treatments. Leveraging natural killer NK cells emerges as a promising […]
  1. Biotechnology
Diagnostics company SphingoTec GmbH (Hennigsdorf, Germany) has successful closed a €5m Series C financing round led by Think.Health Ventures, with support from existing investors Brandenburg Kapital, HBM Healthcare Investments, NRW.BANK, and Wellington Partners. The raised capital will allow the company to reach profitability through partnerships and licence deals of its kidney function test penKid and […]
  1. Biotechnology
At the time of its EU market authorisation application, Gourmey SAS, which has raised €57.8m so far, has applied for authorisation from the competent authorities in the UK, Switzerland, Singapore and the USA. Ivo Rzegotta, responsible for political communication at GFI Europe interest group, described the application as an important signal for the sector: ‘Cultivated […]

Login

Welcome to Life Science News!

"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.